BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Money on the Move: October 20 – 26

  While the volatility of the market has some shying away from going public, private investment dollars are still rolling in each week. Check out our top picks.

  October 27, 2021

   · 

  4 min read

   · 

  Kate Goodwin
• 

  Business

  Teva and MODAG Tie Up on Potential Parkinson’s, MSA Treatment

  Teva Pharmaceuticals inked a deal with MODAG GmbH to license and develop two of MODAG’s compounds in neurodegenerative disease, anle138b and sery433.

  October 27, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  Rep for Wealthy Theranos Stakeholder Describes Holmes’ Investor Courting Practice

  This week during the ongoing trial of Elizabeth Holmes, representatives from one wealthy family described the process with which Holmes secured private investments.

  October 27, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Trial For World’s First Potential Breast Cancer Vaccine Begins

  A large number of people were waiting for the breast cancer vaccine. Now, at present, the world has witnessed the first potential vaccine. Let’s take a look at it.

  October 27, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Deals

  Elevate Bio Takes Gene Editing to Next Level with Life Edit Buy

  With the complete acquisition of Life Edit, ElevateBio will be able to integrate that company’s genome editing capabilities with its cell and gene therapies.

  October 27, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Eli Lilly and Pfizer Put Osteoarthritis Pain Drug Tanezumab Out of its Misery

  The osteoarthritis drug tanezumab gets permanent leave from the market. The decision of stopping production was due to negative feedback from the regulators.

  October 27, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Pharm Country

  Delivery & Safety Top Concerns as BIO-Europe Plumbs Future of Gene Therapy

  Cell and gene therapies are at an inflection point, as increasing quantities of clinical data highlight both their potential and their challenges.

  October 27, 2021

   · 

  4 min read

   · 

  Gail Dutton
• 

  Drug Development

  Takeda Snaps Up Partner GammaDelta to Bolster Oncology Pipeline

  The deal was struck one month after GammaDelta dosed its first patient in a Phase I acute myeloid leukemia (AML) trial.

  October 27, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Cortexyme Puts Positive Spin on Disappointing Phase III Alzheimer’s Results

  The 643-participant study failed to reach statistical significance in its co-primary cognitive and functional endpoints, ADAS-Cog11 and ADCS-ADL, at end of treatment.

  October 27, 2021

   · 

  2 min read

   · 

  Chris Cicinelli
• 

  Pharm Country

  Immunai Scores $215 Million to Accelerate Mapping of the Immune System

  The growth includes the tripling of its headcount to 120 employees and more than 30 partnerships with leading universities and institutions.

  October 27, 2021

   · 

  4 min read

   · 

  Alex Keown